Thermo Fisher Scientific

Articles

Characterization of Biotherapeutic Beasts by Mass Spectrometry

Thursday, September 29, 2022 at 7am PT | 10am ET | 4pm CET Novel methods have been developed and applied on Biotherapeutics Beasts in the half Megadalton to 3-4 MDa range to measure AAV Full:Empty genome ratio using charge detection mass spectrometry on the Q Exactive UHMR mass spectrometer with Direct Mass Technology mode.

Preparing biologics for commercialization: strategies to reduce risk and optimize outcomes

Wednesday, September 28, 2022 at 10 AM EST | 4 PM CET Optimize your late-phase strategy to prepare your biologic for commercialization. CDMO experts share their time-tested best practices on how to adapt for uncertain market demand to get your drug to market on time.

New Developments in Mass Spectrometry-Based Single-Cell Proteomics

Tue, Sep 27, 2022 11:00 AM EDT Learn how Karl Mechtler has developed an end-to-end workflow to efficiently prepare and analyze samples for single-cell proteomics by mass spectrometry. This workflow enables direct injection of single cells to identify approximately 1,500 protein groups per analytical run and uncover the surprising heterogeneity of cell populations.

Building Biotech Series with Brent Cezairliyan

When it comes to biotech, both the academic and industry settings are crucial in developing novel medicines. Dr Brent Cezairliyan has experienced both sides of biotech, first through an academic career exploring bacterial pathogenesis, and now in his administrative role at Octagon Therapeutics. The company, headquartered in Cambridge, Massachusetts, focuses on autoimmune disease treatments. By developing targeted approaches to the inflammatory nature of the immune system, they hope their advances in biotech help future scientists navigate the field for years to come.

mRNA 5’ cap characterization using LC-HRAM-MS

The 5’ capping is a CQA for mRNA vaccines and therapeutics, and needs to be fully characterized. Learn a sensitive, robust LC-HRAM-MS/MS method for identification and quantitation of 5’ cap.

Developing GMP-Manufactured Cas9 Proteins for Therapeutic Applications

Thursday, June 30, 2022 at 11am PST | 1pm CST | 2pm EST As CRISPR based gene editing progresses from research to therapeutic applications, there is a growing need for high quality GMP grade materials, including the Cas9 protein and supporting instruments, and to minimize off target events. This webinar will discuss the development process of a GMP-manufactured Cas9 protein along with causes of off target events and how to minimize risk with high fidelity Cas9 protein.

A complete “how-to” guide for saliva collection and testing

To gain a better appreciation for saliva and its growing use within the diagnostics research market, we’ll take a closer look at some foundational questions about saliva’s composition, physiological function, and its underappreciated history in the medical field.

Building Biotech Series with Joshua Schiffman

After being diagnosed with Hodgkins lymphoma at age 15, Dr Joshua Schiffman was driven to pursue a career in medicine, starting as a pediatric oncologist, and was later drawn to the biotech side of the industry. Dr Schiffman was fascinated with a tidbit of knowledge: elephants almost never get cancer. He met Dr Avi Schroeder at a conference in Israel, and the two wondered how they could take this research about elephants’ cancer-fighting genes and apply it to humans. Together, they co-founded PEEL Therapeutics, the organization’s name meaning elephant in Hebrew, and currently work to bring together nature, medicine, and technology for the betterment of humankind. In this episode, Dr Schiffman provides a hopeful outlook on how nature and biotech can lead scientists to harness the power of evolution and create a bright future for medicine.

Building Biotech Series with Samir Ounzain

While still considering himself a fundamental basic scientist, Samir Ounzain is embracing the biotech industry trend of merging academic research and biotechnological drug development. In this episode, Ounzain talks about his path from a dark theater as a kid watching Jurassic Park to the lab studying the dark matter of the human genome – and eventually to the founding of Haya Therapeutics, a biotech startup aiming to discover and develop safe and effective, tissue- and cell-selective, genome-based therapies for fibrotic diseases.